Safety of a peanut oral immunotherapy protocol in children with peanut allergy.

ABSTRACT:

Background

Oral immunotherapy (OIT) offers a promising therapeutic option for peanut allergy. Given that during OIT an allergic patient ingests an allergen that could potentially cause a serious reaction, the safety of OIT is of particular concern.

Objective

The purpose of this study was to examine safety during the initial escalation day, buildup phase, and home dosing phase in subjects enrolled in a peanut OIT study.

Methods

Skin, upper respiratory tract, chest, and abdominal symptoms were recorded with initial escalation day and buildup phase dosings. Subjects also maintained daily diaries detailing symptoms after each home dosing. A statistical analysis of these data was performed.

Results

Twenty of 28 patients completed all phases of the study. During the

SUBMITTER: Hofmann AM 

PROVIDER: S-EPMC2731305 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature